A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

References

• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Farrand KF, Fridman M, Stillman I, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98. doi:10.1016/j.ajo.2017.06.033
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–365. doi:10.1016/j.jtos.2017.05.003
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–2292. doi:10.2147/OPTH.S226168
   PubMed Web of Science ®Google Scholar
• McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016;14(2):144–167. doi:10.1016/j.jtos.2015.11.002
   PubMed Web of Science ®Google Scholar
• Barber L, Khodai O, Croley T, et al. Dry eye symptoms and impact on vision-related function across international task force guidelines severity levels in the United States. BMC Ophthalmol. 2018;18(1):260. doi:10.1186/s12886-018-0919-7
   Web of Science ®Google Scholar
• Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman I. Comorbidities and prescribed medications in patients with or without dry eye disease: a population-based study. Am J Ophthalmol. 2019;198:181–192. doi:10.1016/j.ajo.2018.10.001
   Web of Science ®Google Scholar
• Han SB, Yang HK, Hyon JY, Wee WR. Association of dry eye disease with psychiatric or neurological disorders in elderly patients. Clin Interv Aging. 2017;12:785–792. doi:10.2147/CIA.S137580
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Depression and anxiety in dry eye disease: a systematic review and meta-analysis. Eye. 2016;30(12):1558–1567. doi:10.1038/eye.2016.186
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wu X, Lin X, Lin H. The prevalence of depression and depressive symptoms among eye disease patients: a systematic review and meta-analysis. Sci Rep. 2017;7(1):46453. doi:10.1038/srep46453
   PubMed Web of Science ®Google Scholar
• Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs. 2007;67(9):1291–1308. doi:10.2165/00003495-200767090-00004
   PubMed Web of Science ®Google Scholar
• Al Hanaineh AT, Hassanein DH, Abdelbaky SH, El Zawahry OM. Steroid-induced ocular hypertension in the pediatric age group. Eur J Ophthalmol. 2018;28(4):372–377. doi:10.1177/1120672118757434
   PubMed Web of Science ®Google Scholar
• Lollett IV, Galor A. Dry eye syndrome: developments and lifitegrast in perspective. Clin Ophthalmol. 2018;12:125–139. doi:10.2147/OPTH.S126668
   PubMed Web of Science ®Google Scholar
• Incorporated SU.XIIDRA^TM (lifitegrast ophthalmic solution)5%, for topical ophthalmic use. 06/2016. MA: Shire US Incorporated; 2016.
   Google Scholar
• Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: physician’s evaluation of restasis(®) satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971–1976. doi:10.2147/OPTH.S30261
   PubMedGoogle Scholar
• Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. Clin Ophthalmol. 2018;12:263–270. doi:10.2147/OPTH.S152841
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol. 2020;14:875–883. doi:10.2147/OPTH.S233194
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease. Clin Ophthalmol. 2020;14:931–938. doi:10.2147/OPTH.S237832
   PubMed Web of Science ®Google Scholar
• Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021;37(4):193–199. doi:10.1089/jop.2020.0087
   PubMed Web of Science ®Google Scholar
• Clark D, Tauber J, Sheppard J, Brady TC. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22–31. doi:10.1016/j.ajo.2021.01.011
   PubMed Web of Science ®Google Scholar
• Clark D, Cavanagh B, Shields AL, et al. Clinically relevant activity of the novel rasp inhibitor reproxalap in allergic conjunctivitis: the Phase 3 ALLEVIATE trial. Am J Ophthalmol. 2021;230:60–67. doi:10.1016/j.ajo.2021.04.023 
   Web of Science ®Google Scholar
• Mandell KJ, Clark D, Chu DS, Foster CS, Sheppard J, Brady TC. Randomized Phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement. J Ocul Pharmacol Ther. 2020;36(10):732–739. doi:10.1089/jop.2020.0056
   PubMed Web of Science ®Google Scholar
• Olsen MF, Bjerre E, Hansen MD, et al. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017;15(1):35. doi:10.1186/s12916-016-0775-3
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed August 1, 2021.
   Google Scholar